SummaryOlaparib is the study intervention in this trial. Olaparib (LynparzaTM) is a poly(ADP-ribose) polymerase (PARP) inhibitor. The inactive ingredients are copovidone, colloidal silicon dioxide, mannitol, sodium stearyl fumarate, hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black.
It is provided as tablets each containing 100mg or 150mg olaparib for oral administration. administered as 300 mg orally twice daily until disease progression or unacceptable toxicity. Each bottle contains 32 tablets. Patients will be asked to return unused drug and empty drug containers at each return visit for adherence.
Olaparib should be commenced within 7 days after registration and will be continued until disease progression or unacceptable toxicity.
This trial is treating patients with triple negative breast or ovarian cancers that don't have the BRCA1 or BRCA2 mutation.
The EMBRACE study
Use the hyperlinks, where available to access additional clinical trial information.
Cancer Australia, Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2